A New Era in Relieving the Burden and Improving Health Outcomes of Children with Growth Hormone Deficiency

TARGET AUDIENCE:
This activity was developed for pediatric endocrinologists, pediatricians, nurse practitioners, physician assistants and other healthcare providers who treat children and adolescents with growth and growth hormone disorders.

PROGRAM OVERVIEW:
Growth hormone deficiency (GHD) specialists Sara DiVall, MD, and Kevin Yuen, MD, explore ways to optimize outcomes in the diagnosis and treatment of GHD in children, including considerations for the use of long-acting growth hormone (LAGH) products. Topics include the epidemiology, clinical manifestations, and burden of GHD in children and adolescents, evidence-based diagnosis of GHD, guidelines and recommendations for treatment, integrating shared decision-making with patients and/or their parents to develop and modify the treatment plan, and clinical trial data regarding daily and new and emerging LAGH products. Case studies based on common clinical scenarios are discussed to examine how to apply this information in clinical practice to optimize long-term self-management.

CONTENT AREAS
• Epidemiology
• Burden of GHD
• Shared Decision-Making
• Somatropin Products
• New/Emerging Long-acting Growth Hormone Products
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
• Implement key treatment recommendations for children and adolescents with growth hormone deficiency (competence)
• Implement shared decision-making to help children and adolescents and their parents select a growth hormone product based on patient characteristics and needs and product labeling (competence)
• Initiate, titrate, and monitor growth hormone therapy in children and adolescents based on patient response and tolerability (competence)
• Describe the safety and efficacy of emerging long-acting recombinant humangrowth hormone therapies and their potential use in children and adolescents (knowledge)